- Email: [email protected]
P1.03-024 Efficacy of Carboplatin-Vinorelbine in Advanced NSCLC Patients at Persahabatan Hospital, Jakarta - Indonesia
S1960 combined with cytotoxic drugs was also suitable as the second-line treatment for such patients. Keywords: bevacizumab, lung adenocarcinoma, chemotherapy
Journal of Thoracic Oncology
Vol. 12 No. 11S2
chemotherapy regimen. Conclusion: Combination of carboplatin and vinorelbine as first line chemotherapy has a good efficacy and tolerability for advanced NSCLC subjects. Keywords: carboplatin and vinorelbine combination, tolerability, advanced NSCLC
P1.03-025 Combination Therapy with Carboplatin and Hyperoxia Synergistically Enhances Suppression of Benzo[a] Pyrene Induced Lung Cancer S.H. Lee,1 S.K. Kim,2 C.K. Park,3 J.W. Kim,4 S.J. Kim,5 H.S. Moon1 1 Division of Pulmonology, Department of Internal Medicine, St. Paul’s Hospital, Catholic University of Korea, Seoul/KR, 2Division of Pulmonology, Department of Internal Medicine, St. Vincent’s Hospital, Catholic University of Korea, Gyeonggido/KR, 3Division of Pulmonology, Department of Internal Medicine, Yeouido St. Mary’s Hospital, Catholic University of Korea, Seoul/KR, 4Division of Pulmonology, Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, Catholic University of Korea, Geonggido/KR, 5Division of Pulmonology, Department of Internal Medicine, Seoul St. Mary’s Hospital, Catholic University of Korea, Seoul/ KR
P1.03-024 Efficacy of Carboplatin-Vinorelbine in Advanced NSCLC Patients at Persahabatan Hospital, Jakarta Indonesia P. Diah,1 S. Andarini,2 J. Zaini,2 E. Syahruddin,1 A. Hudoyo1 1Faculty of Medicine University of Indonesia - Persahabatan Hospital, Department of Pulmonology and Respiratory Medicine, Jakarta/ID, 2Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Persahabatan Hospital, Jakarta/ID Background: Combination of platinum-based and third generation drugs such as vinorelbine chemotherapy are frequently used as palliative chemotherapy for Non-small cell lung cancer (NSCLC) patients in Indonesia especially in Persahabatan Hospital. But there is still no data about the efficacy and tolerability of carboplatin-vinorelbine regimen. This study was conducted to evaluate the efficacy and toxicity of this regimen as first line chemotherapy for advanced NSCLC patients in Persahabatan Hospital. Method: This study was an observational study in advanced NSCLC patients who receive carboplatin-vinorelbine regimen as first line chemotherapy. Subjects were recruited between 1 January 2015 to 30 March 2017. Clinical data regarding the histological type, staging, side effect of chemotherapy, RECIST and survival were recorded. Result: Thirty eight subjects were recruited in this study of which carboplatin 5 AUC on day 1 and vinorelbine 30mg/m2 on day 1 and 8 were administered as a combination therapy. This regimen has a good efficacy with overall response rate (ORR) 12,5% and clinical benefit rate (CBR) 87,5%. The overall survival (OS) 34,2% with median of survival time 387 days (12,9 moths) and progression free survival (PFS) 323 days (10,7 months). We found grade 1 anemia (38,4%) and grade 2 nausea vomiting (57,9%) as hematological and non-hematological toxicity that frequently occurred in this study. Two cases of grade 2 gastrointestinal bleeding were observed but the subjects still were able to continue the chemotherapy soon after recovery. Mild phlebitis were observed in 65.7% cases (24 subjects) and moderate phlebitis in 2.6% (1 subject) as procedural complication of this
Background: We explored the effects of intermittent normobaric hyperoxia alone or combined with chemotherapy on the growth, general morphology, oxidative stress, and apoptosis of benzo[a]pyrene (B [a]P)-induced lung tumors in mice. Method: Female A/J mice were given a single dose of B[a]P and randomized into four groups: (1) control, (2) carboplatin (50 mg/kg intraperitoneally), (3) hyperoxia (95% fraction of inspired oxygen), and (4) carboplatin and hyperoxia. Normobaric hyperoxia (95%) was applied for 3 h each day from weeks 21 to 28. Tumor load was determined as the average total tumor numbers and volumes. Several markers of oxidative stress and apoptosis were evaluated. Result: Intermittent normobaric hyperoxia combined with chemotherapy reduced the tumor number by 59% and the load by 72% compared with the control B[a]P group. Intermittent normobaric hyperoxia, either alone or combined with chemotherapy, decreased the levels of superoxide dismutase (SOD) and glutathione (GSH) and increased the levels of catalase and 8-hydroxydeoxyguanosine (8-OHdG). The Bax/Bcl-2 mRNA ratio, caspase-3 level, and number of transferase-mediated dUTP nick end-labeling (TUNEL)positive cells increased following treatment with hyperoxia with or without chemotherapy. Conclusion: Intermittent normobaric hyperoxia was found to be tumoricidal and thus may serve as an adjuvant therapy for lung cancer. Oxidative stress and its effects on DNA are increased following exposure to hyperoxia and even more with chemotherapy, and this may lead to apoptosis of lung tumors. Keywords: carboplatin, lung cancer, hyperoxia
P1.03-026 Interim Results of a Phase I Study of Nivolumab plus Nab-Paclitaxel/Carboplatin in Patients with NSCLC J.W. Goldman,1 D. Waterhouse,2 B. George,3 P. O’Dwyer,4 T. Chen,5 N. Trunova,5 K. Kelly6 1University of California at Los Angeles, Santa Monica, CA/US, 2Oncology Hematology Care, Cincinnati, OH/US, 3 Froedtert and the Medical College of Wisconsin, Milwaukee, WI/US, 4 University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA/ US, 5Celgene Corporation, Summit, NJ/US, 6University of California Davis Comprehensive Cancer Center, Sacramento, CA/US Background: Chemotherapy, including taxanes, may augment the effects of immune checkpoint inhibitors through tumor cell lysis and subsequent antigen release. This phase I trial is evaluating safety and efficacy of nivolumab plus nab-paclitaxel in NSCLC (+ carboplatin), pancreatic cancer (± gemcitabine), and metastatic breast cancer.
Journal of Thoracic Oncology
Vol. 12 No. 11S2
chemotherapy regimen. Conclusion: Combination of carboplatin and vinorelbine as first line chemotherapy has a good efficacy and tolerability for advanced NSCLC subjects. Keywords: carboplatin and vinorelbine combination, tolerability, advanced NSCLC
P1.03-025 Combination Therapy with Carboplatin and Hyperoxia Synergistically Enhances Suppression of Benzo[a] Pyrene Induced Lung Cancer S.H. Lee,1 S.K. Kim,2 C.K. Park,3 J.W. Kim,4 S.J. Kim,5 H.S. Moon1 1 Division of Pulmonology, Department of Internal Medicine, St. Paul’s Hospital, Catholic University of Korea, Seoul/KR, 2Division of Pulmonology, Department of Internal Medicine, St. Vincent’s Hospital, Catholic University of Korea, Gyeonggido/KR, 3Division of Pulmonology, Department of Internal Medicine, Yeouido St. Mary’s Hospital, Catholic University of Korea, Seoul/KR, 4Division of Pulmonology, Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, Catholic University of Korea, Geonggido/KR, 5Division of Pulmonology, Department of Internal Medicine, Seoul St. Mary’s Hospital, Catholic University of Korea, Seoul/ KR
P1.03-024 Efficacy of Carboplatin-Vinorelbine in Advanced NSCLC Patients at Persahabatan Hospital, Jakarta Indonesia P. Diah,1 S. Andarini,2 J. Zaini,2 E. Syahruddin,1 A. Hudoyo1 1Faculty of Medicine University of Indonesia - Persahabatan Hospital, Department of Pulmonology and Respiratory Medicine, Jakarta/ID, 2Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Persahabatan Hospital, Jakarta/ID Background: Combination of platinum-based and third generation drugs such as vinorelbine chemotherapy are frequently used as palliative chemotherapy for Non-small cell lung cancer (NSCLC) patients in Indonesia especially in Persahabatan Hospital. But there is still no data about the efficacy and tolerability of carboplatin-vinorelbine regimen. This study was conducted to evaluate the efficacy and toxicity of this regimen as first line chemotherapy for advanced NSCLC patients in Persahabatan Hospital. Method: This study was an observational study in advanced NSCLC patients who receive carboplatin-vinorelbine regimen as first line chemotherapy. Subjects were recruited between 1 January 2015 to 30 March 2017. Clinical data regarding the histological type, staging, side effect of chemotherapy, RECIST and survival were recorded. Result: Thirty eight subjects were recruited in this study of which carboplatin 5 AUC on day 1 and vinorelbine 30mg/m2 on day 1 and 8 were administered as a combination therapy. This regimen has a good efficacy with overall response rate (ORR) 12,5% and clinical benefit rate (CBR) 87,5%. The overall survival (OS) 34,2% with median of survival time 387 days (12,9 moths) and progression free survival (PFS) 323 days (10,7 months). We found grade 1 anemia (38,4%) and grade 2 nausea vomiting (57,9%) as hematological and non-hematological toxicity that frequently occurred in this study. Two cases of grade 2 gastrointestinal bleeding were observed but the subjects still were able to continue the chemotherapy soon after recovery. Mild phlebitis were observed in 65.7% cases (24 subjects) and moderate phlebitis in 2.6% (1 subject) as procedural complication of this
Background: We explored the effects of intermittent normobaric hyperoxia alone or combined with chemotherapy on the growth, general morphology, oxidative stress, and apoptosis of benzo[a]pyrene (B [a]P)-induced lung tumors in mice. Method: Female A/J mice were given a single dose of B[a]P and randomized into four groups: (1) control, (2) carboplatin (50 mg/kg intraperitoneally), (3) hyperoxia (95% fraction of inspired oxygen), and (4) carboplatin and hyperoxia. Normobaric hyperoxia (95%) was applied for 3 h each day from weeks 21 to 28. Tumor load was determined as the average total tumor numbers and volumes. Several markers of oxidative stress and apoptosis were evaluated. Result: Intermittent normobaric hyperoxia combined with chemotherapy reduced the tumor number by 59% and the load by 72% compared with the control B[a]P group. Intermittent normobaric hyperoxia, either alone or combined with chemotherapy, decreased the levels of superoxide dismutase (SOD) and glutathione (GSH) and increased the levels of catalase and 8-hydroxydeoxyguanosine (8-OHdG). The Bax/Bcl-2 mRNA ratio, caspase-3 level, and number of transferase-mediated dUTP nick end-labeling (TUNEL)positive cells increased following treatment with hyperoxia with or without chemotherapy. Conclusion: Intermittent normobaric hyperoxia was found to be tumoricidal and thus may serve as an adjuvant therapy for lung cancer. Oxidative stress and its effects on DNA are increased following exposure to hyperoxia and even more with chemotherapy, and this may lead to apoptosis of lung tumors. Keywords: carboplatin, lung cancer, hyperoxia
P1.03-026 Interim Results of a Phase I Study of Nivolumab plus Nab-Paclitaxel/Carboplatin in Patients with NSCLC J.W. Goldman,1 D. Waterhouse,2 B. George,3 P. O’Dwyer,4 T. Chen,5 N. Trunova,5 K. Kelly6 1University of California at Los Angeles, Santa Monica, CA/US, 2Oncology Hematology Care, Cincinnati, OH/US, 3 Froedtert and the Medical College of Wisconsin, Milwaukee, WI/US, 4 University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA/ US, 5Celgene Corporation, Summit, NJ/US, 6University of California Davis Comprehensive Cancer Center, Sacramento, CA/US Background: Chemotherapy, including taxanes, may augment the effects of immune checkpoint inhibitors through tumor cell lysis and subsequent antigen release. This phase I trial is evaluating safety and efficacy of nivolumab plus nab-paclitaxel in NSCLC (+ carboplatin), pancreatic cancer (± gemcitabine), and metastatic breast cancer.